Literature DB >> 11220741

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy.

J C Antoine1, J Honnorat, J P Camdessanché, M Magistris, L Absi, J F Mosnier, P Petiot, N Kopp, D Michel.   

Abstract

Subacute sensory neuronopathy with anti-Hu antibodies is the best-characterized paraneoplastic peripheral neuropathy associated with carcinoma. Anti-CV2 antibodies, another group of paraneoplastic antibodies, react with a 66-kd brain protein belonging to the family of Ulip/CRMP proteins. The manifestations associated with anti-CV2 antibodies include cerebellar degeneration, uveitis, and peripheral neuropathy. Some of these patients also have anti-Hu antibodies. We have compared the clinical, electrophysiological, and pathological characteristics of the peripheral neuropathy in 9 patients with anti-CV2 antibodies (3 of whom also had anti-Hu antibodies) and 12 patients with only anti-Hu antibodies. Data for patients with anti-Hu antibodies alone indicated subacute sensory neuronopathy. Patients with anti-CV2 antibodies had a mixed axonal and demyelinating sensory motor neuropathy that was sometimes superimposed on subacute sensory neuronopathy when both anti-CV2 and anti-Hu antibodies were present. Unlike anti-Hu antibodies, anti-CV2 antibodies reacted with peripheral nerve antigens, as shown by their ability to bind to a 66-kd protein in human and rat nerve on Western blot analysis and to immunolabel peripheral nerve axons and sensory neurons on immunohistochemical study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220741     DOI: 10.1002/1531-8249(20010201)49:2<214::aid-ana41>3.0.co;2-w

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

Review 1.  Paraneoplastic syndromes of the CNS.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Lancet Neurol       Date:  2008-04       Impact factor: 44.182

Review 2.  Diagnosis of acute neuropathies.

Authors:  Clarissa Crone; Christian Krarup
Journal:  J Neurol       Date:  2007-09-21       Impact factor: 4.849

3.  Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data.

Authors:  M Tschernatsch; E Stolz; M Strittmatter; M Kaps; F Blaes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

Review 4.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 5.  Atypical Optic Neuritis.

Authors:  Eric D Gaier; Katherine Boudreault; Joseph F Rizzo; Julie Falardeau; Dean M Cestari
Journal:  Curr Neurol Neurosci Rep       Date:  2015-12       Impact factor: 5.081

Review 6.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

Review 7.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

Review 8.  Neurologic paraneoplastic syndromes.

Authors:  Edward J Dropcho
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 9.  Update on neurological paraneoplastic syndromes.

Authors:  Romana Höftberger; Myrna R Rosenfeld; Josep Dalmau
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

10.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.

Authors:  J Honnorat; S Cartalat-Carel; D Ricard; J Ph Camdessanche; A F Carpentier; V Rogemond; F Chapuis; M Aguera; E Decullier; A M Duchemin; F Graus; J C Antoine
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10-17       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.